Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials
- PMID: 30760112
- PMCID: PMC7063818
- DOI: 10.1080/16506073.2018.1560358
Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials
Abstract
The purpose of this meta-analysis was to provide updated pooled effect sizes of evidence-based psychotherapies and medications for generalized anxiety disorder (GAD) and to investigate potential moderators of outcomes. Seventy-nine randomized controlled trials (RCT) including 11,002 participants with a diagnosis of GAD were included in a meta-analysis that tested the efficacy of psychotherapies or medications for GAD. Psychotherapy showed a medium to large effect size (g = 0.76) and medication showed a small effect size (g = 0.38) on GAD outcomes. Psychotherapy also showed a medium effect on depression outcomes (g = 0.64) as did medications (g = 0.59). Younger age was associated with a larger effect size for psychotherapy (p < 0.05). There was evidence of publication bias in psychotherapy studies. This analysis found a medium to large effect for empirically supported psychotherapy interventions on GAD outcomes and a small effect for medications on GAD outcomes. Both groups showed a medium effect on depression outcomes. Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly. Patient age should be further investigated as a potential moderator in psychotherapy outcomes in GAD.
Keywords: GAD; generalized anxiety disorder; medication; meta-analysis: randomized controlled trial; therapy.
Conflict of interest statement
Disclosure statement
No potential conflict of interest was reported by the authors.
Figures
References
-
- Alaka KJ, Noble W, Montejo A, Dueñas H, Munshi A, Strawn JR, … Ball S (2014). Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: A randomized, double-blind, placebo-controlled trial. International Journal of Geriatric Psychiatry, 29(9), 978–986. doi: 10.1002/gps.4088 - DOI - PMC - PubMed
-
- Aliyev NA, & Aliyev ZN (2008). Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study. European Psychiatry : the Journal of the Association of European Psychiatrists, 23(2), 109–114. doi: 10.1016/j.eurpsy.2007.08.001 - DOI - PubMed
-
- Allgulander C, Hackett D, & Salinas E (2001). Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. The British Journal of Psychiatry : the Journal of Mental Science, 179(1), 15–22. doi: 10.1192/bjp.179.1.15 - DOI - PubMed
-
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5. Washington DC: American Psychiatric Association.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical